New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket.

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US ...

STORY: Shares of Novo Nordisk tumbled 10% Monday morning after the drugmaker revealed weaker-than-expected data about its ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Shares of Novo Nordisk (NVO) trading in New York are down $5.22, or 6%, to $81.95 in the pre-market session.Discover the Best Stocks and ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...